Search

everythinglearnresearchcommunity

for

Search:↓

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

CXXC5 can both suppress and promote cancer, making it a complex target for treatment.

Androgen self-administration might be controlled by membrane receptors, not nuclear ones.

New nanocarriers were developed for safer, targeted drug delivery and diagnostics, showing promise for future medical use.

Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.

Liposomes can make the antiandrogen RU 58841 more effective for skin application by reducing absorption, increasing skin retention, and targeting sebaceous structures.

Steroid hormone binding in rat skin varies with pH, heat, and hair cycle phases.

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.

Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.

Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.

GI197111X is best dissolved in Capmul MCM for trials.

Mitochondria may influence how cells respond to radiation, affecting nearby non-irradiated cells.

Ca 45 mainly enters rat skin and eye through biosynthesis and may be adsorbed in cartilage and glands.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

A new treatment using a DNA aptamer can promote hair growth by targeting a specific receptor.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

FGF9 controls which receptors it binds to through a process where two FGF9 molecules join, and changes in FGF9 can lead to incorrect receptor activation.

The new assay can help develop products for hair re-growth.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.

Promising cancer treatments were found, but the manufacturer closed.

dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.